The grant awarded for Chadli’s research focuses on a specific protein, UNC45A, that can be used as a promising novel immunotherapeutic target in treating triple-negative breast cancer (TNBC).
Ali Arbab, MD, has been awarded a grant by the National Institute of Neurological Disorders and Stroke (NINDS), demonstrating the translational ability of his new technology.